

ORE PHARMACEUTICAL HOLDINGS INC. (ORXE)

8-K

Current report filing

Filed on 02/12/2010

Filed Period 02/12/2010



THOMSON REUTERS

Westlaw[®] BUSINESS

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2010

ORE PHARMACEUTICAL HOLDINGS INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-23317 (Commission File Number)	27-1088078 (IRS Employer Identification No.)
---	-------------------------------------	--

One Main Street, Suite 300
Cambridge, Massachusetts 02142
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (617) 649-2001

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a), (c), (d), (e) and (f): Not applicable.

(b) On February 12, 2010, James W. Fordyce informed Ore Pharmaceutical Holdings Inc. (the "Company") of his resignation from the board of directors of the Company effective as of February 12, 2010. The Company believes that Mr. Fordyce's decision to resign was not due to any disagreement on any matters relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORE PHARMACEUTICAL HOLDINGS INC.

Dated: February 12, 2010

/s/ BENJAMIN L. PALLEIKO

Benjamin L. Palleiko
Senior Vice President and Chief Financial